西达本胺治疗乳腺肿瘤的研究进展

Research progression in the treatment of breast tumors with Chidamide

西达本胺是我国自主研发合成的首个亚型选择性组蛋白脱乙酰化酶抑制剂(HDACi),属于表观遗传学相关药物。组蛋白是人体内染色体的基本组成单位之一,其乙酰化作用在肿瘤的发生发展中扮演着重要角色。研究显示,组蛋白脱乙酰化酶(HDAC)在细胞中过量表达时,会导致乙酰化失衡现象,进而诱导肿瘤发生。因此,抑制HDAC的作用已成为肿瘤治疗的重要途径之一。

Chidamide is the first subtype selective histone deacetylase(HDAC)inhibitor independently developed and synthesized in China,belonging to epigenetic drugs.Histone is one of the basic components of human chromosomes,and its acetylation plays an important role in the development of tumors.Studies have shown that when HDAC is overexpressed in cells,it can lead to an acetylation imbalance,which in turn induces tumorigenesis.Therefore,inhibiting the effect of HDAC has become one of the important approaches of tumor therapy.